CARE研究PPT课件.pptVIP

Fatal CHD or Nonfatal Myocardial Infarction (Primary Endpoint) CABG/PTCA/Combined 26% reduction (p=0.005) PTCA 23% reduction (p=0.01) Combined CABG/PTCA 27% risk reduction (p0.001) Other: Stroke 31% reduction (p=0.03) The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels Frank M. Sacks, M.D., Marc A. Pfeffer, M.D., Ph.D., Lemuel A. Moye, M.D., Ph.D., Jean L. Rouleau, M.D., J. Malcolm O. Arnold, M.D., Chuan-Chuan Wun, Ph.D., Barry Davis, M.D., Ph.D., Eugene Braunwald, M.D., for the Cholesterol and Recurrent Events Trial Investiga